High-Dose Basic Drug Tablets With Surfactant-Aided Dissolution

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Poorly soluble basic agents, such as the compound represented by formula (I), face challenges in achieving high-dose formulations with good disintegration and dissolution, leading to low oral absorbability due to the formation of impermeable films during tablet disintegration.

Innovation Solution

A pharmaceutical composition comprising a compound represented by formula (I) or its salt, an anionic surfactant like sodium lauryl sulfate, and a basic substance such as magnesium aluminometasilicate, with specific weight ratios and amounts, to prevent film formation and enhance dissolution.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If a high-dose formulation is used to increase absorption of a poorly soluble basic agent, then the dosage strength is improved, but the dissolution and oral absorbability worsen due to stronger poor solubility at high doses

Engineering Contradiction:
Improvedosage strengthVSAvoiddissolution and oral absorbability
Core Design Contradiction:
Quantity of substanceVSReliability

Solution Approach 1:

A water-soluble basic substance (mediator) is introduced into the formulation to interact with the poorly soluble basic agent. This intermediary substance forms a soluble complex or salt with the drug compound, enabling high-dose formulations to dissolve properly in gastrointestinal fluids. The mediator bridges the gap between the insoluble drug and the aqueous environment needed for absorption.

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The formulation changes the chemical parameters of the poorly soluble basic agent by converting it into a soluble form through interaction with the water-soluble basic substance. This parameter change (from insoluble to soluble state) enables high-dose formulations to maintain good dissolution properties despite the increased drug load.

Inventive Principle:
Principle #35Parameter changes

2Ease of manufacture

If a poorly soluble basic agent is compressed into tablets, then the formulation is improved for oral administration, but an impermeable film forms during disintegration that prevents further dissolution

Engineering Contradiction:
Improvetablet formulationVSAvoiddisintegration and dissolution
Core Design Contradiction:
Ease of manufactureVSReliability

Solution Approach 1:

The water-soluble basic substance acts as an intermediary that prevents film formation during tablet disintegration. It interacts with the poorly soluble basic agent to maintain solubility throughout the disintegration process, ensuring that no impermeable film forms to block further dissolution. This mediator ensures continuous solubility from tablet disintegration through to complete dissolution.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If dissolution aids are used to improve dissolution of poorly soluble basic agents, then the dissolution rate is improved, but the formulation complexity increases

Engineering Contradiction:
Improvedissolution rateVSAvoidformulation complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The water-soluble basic substance serves multiple functions simultaneously: it acts as a dissolution aid to improve dissolution rate, as a formulation enabler to allow high-dose formulations, and as a solubility enhancer to prevent film formation. This multi-functionality reduces the need for multiple separate additives, thereby simplifying the overall formulation despite achieving multiple goals.

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The composition achieves high-dose tablets with good dissolution and disintegration, reducing dosing frequency and improving drug compliance by preventing impermeable film formation and enhancing oral absorbability.

Implementation Method 1

A pharmaceutical formulation which comprises, as an active ingredient, a poorly soluble basic agent such as compound (I) or a salt thereof typically has low absorption when orally administered

Methodology Applied
Scientific EffectSurfactant: Surfactant

Data Source

PatentUS12564594B2Pharmaceutical composition containing 9-ethyl-6, 6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6, 11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
Publication Date: 2026.03.03 CHUGAI PHARMA CO LTD
  • US12564594B2 patent drawing
  • US12564594B2 patent drawing
  • US12564594B2 patent drawing

AI summary

The present invention aims to provide a high-dose formulation with improved properties of a pharmaceutical composition comprising a poorly soluble basic agent, particularly a compound represented by formula (I) or a salt thereof. The problem described above can be solved by providing a pharmaceutical composition comprising the compound represented by formula (I) or a salt thereof, a surfactant, and a basic substance.